Trial · NCT07165886
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
NCT07165886, Phase 2, Phase 3, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors. Trials, record NCT07165886. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07165886
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
- NCT number
- NCT07165886
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 298 participants, estimated
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus
- First posted
- 2025-09-10
- Last updated
- 2026-04-24
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase II: Incidences of Adeverse Events (AEs) | Up to 3 years | |
| Primary | Phase II: Dose Limiting Toxicity (DLT) | Up to 1 year | |
| Primary | Phase II: Recommended Phase 3 Dose (RP3D) | Up to 1 year | |
| Primary | Phase II: Objective Response Rate (ORR） per investigator | Up to 1 year | |
| Primary | Phase III: Progression Free Survival (PFS) per Blinded Independent Review Committee (BIRC) | Up to 3 years | |
| Secondary | Phase II: Duration of Response (DOR) per investigator | Up to 3 years | |
| Secondary | Phase II: Disease Control Rate (DCR) per investigator | Up to 3 years | |
| Secondary | Phase II: Progression Free Survival (PFS) per investigator | Up to 3 years | |
| Secondary | Phase II: Overall Survival (OS) | Up to 3 years | |
| Secondary | Peak Concentration：Cmax | Up to 3 years |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07165886
GET https://conductscience.org/api/trials/v1/NCT07165886/registered?page=2